Cover Image
市場調查報告書

CoLucid Pharmaceuticals, Inc. - 產品平台分析

CoLucid Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253772
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
CoLucid Pharmaceuticals, Inc. - 產品平台分析 CoLucid Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年05月27日 內容資訊: 英文 25 Pages
簡介

CoLucid Pharmaceuticals, Inc. 是開發中樞神經障礙治療藥的製藥公司。該公司代表性產品lasmiditan是作用於神經的抗偏頭痛藥,同時在其他疾病治療上也有抑制血管收縮的效果。此外也提供針對具有心血管疾病危險因子的患者、或triptan無效的患者有效的產品。

本報告提供CoLucid Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

CoLucid Pharmaceuticals, Inc.的基本資料

CoLucid Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

CoLucid Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

CoLucid Pharmaceuticals, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

CoLucid Pharmaceuticals, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

CoLucid Pharmaceuticals, Inc.:藥物簡介

  • lasmiditan succinate
  • COL-204
  • Conjugated Stigmine Program

CoLucid Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

CoLucid Pharmaceuticals, Inc.:最近的開發平台趨勢

CoLucid Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07140CDB

Summary

Global Markets Direct's, 'CoLucid Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the CoLucid Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CoLucid Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of CoLucid Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CoLucid Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CoLucid Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate CoLucid Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CoLucid Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CoLucid Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CoLucid Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CoLucid Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CoLucid Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CoLucid Pharmaceuticals, Inc. Snapshot
    • CoLucid Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • CoLucid Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • CoLucid Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • CoLucid Pharmaceuticals, Inc. - Pipeline Products Glance
    • CoLucid Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • CoLucid Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • CoLucid Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • CoLucid Pharmaceuticals, Inc. - Drug Profiles
    • lasmiditan succinate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • COL-204
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Conjugated Stigmine Program
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • CoLucid Pharmaceuticals, Inc. - Pipeline Analysis
    • CoLucid Pharmaceuticals, Inc. - Pipeline Products by Target
    • CoLucid Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • CoLucid Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • CoLucid Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • CoLucid Pharmaceuticals, Inc. - Recent Pipeline Updates
  • CoLucid Pharmaceuticals, Inc. - Dormant Projects
  • CoLucid Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CoLucid Pharmaceuticals, Inc., Key Information
  • CoLucid Pharmaceuticals, Inc., Key Facts
  • CoLucid Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • CoLucid Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • CoLucid Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • CoLucid Pharmaceuticals, Inc. - Phase III, 2015
  • CoLucid Pharmaceuticals, Inc. - Phase II, 2015
  • CoLucid Pharmaceuticals, Inc. - Preclinical, 2015
  • CoLucid Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • CoLucid Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • CoLucid Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • CoLucid Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • CoLucid Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • CoLucid Pharmaceuticals, Inc. - Dormant Developmental Projects,2015

List of Figures

  • CoLucid Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • CoLucid Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • CoLucid Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • CoLucid Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • CoLucid Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • CoLucid Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • CoLucid Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top